Derivation and Characterization of a Transgene-free Human Induced Pluripotent Stem Cell Line and Conversion into Defined Clinical-grade Conditions
November 26th, 2014
7.4K views
We describe a protocol for deriving lentiviral-based reprogrammed and characterized factor-free human induced pluripotent stem cells and conversion into putative clinical-grade conditions.
Overview
This article describes a protocol for deriving lentiviral-based reprogrammed and characterized factor-free human induced pluripotent stem cells (hiPSCs) and converting them into putative clinical-grade conditions. The methodology emphasizes the reprogramming of adult dermal human fibroblasts and the subsequent conversion of hiPSCs into clinically relevant conditions.
Key Study Components
Area of Science
- Stem cell biology
- Cell reprogramming
- Clinical applications of stem cells
Background
- Human induced pluripotent stem cells (hiPSCs) are valuable for regenerative medicine.
- Reprogramming adult cells can provide a source of patient-specific stem cells.
- Factor-free reprogramming reduces the risk of genomic integration of foreign DNA.
- Clinical-grade conditions are essential for therapeutic applications.
Purpose of Study
- To develop a reliable protocol for generating hiPSCs from adult fibroblasts.
- To ensure the removal of reprogramming factors from the host genome.
- To convert hiPSCs into conditions suitable for clinical use.
Methods Used
- Reprogramming adult dermal fibroblasts using a lentiviral stem cell cassette.
- Exposing reprogrammed hiPSCs to adeno-Cre virus for excision of the stem cell cassette.
- Genomic DNA extraction and analysis to confirm proper excision.
- Conversion of hiPSCs into defined xeno-free conditions for clinical applications.
Main Results
- Successful reprogramming of fibroblasts into hiPSCs.
- Effective excision of the stem cell cassette from the genome.
- Conversion of hiPSCs into putative GMP-grade conditions.
- Demonstration of the methodology's broad applicability for clinical relevance.
Conclusions
- The protocol provides a robust method for generating clinically relevant hiPSCs.
- Factor-free reprogramming enhances safety for therapeutic applications.
- This approach can be applied to various adult human cells for reprogramming.
Frequently Asked Questions
What are hiPSCs?
Human induced pluripotent stem cells (hiPSCs) are stem cells that can be generated directly from adult cells.
Why is factor-free reprogramming important?
Factor-free reprogramming minimizes the risk of genomic integration of foreign DNA, enhancing safety for clinical applications.
What is the significance of GMP-grade conditions?
GMP-grade conditions ensure that stem cells are produced in compliance with regulatory standards for clinical use.
How are adult fibroblasts reprogrammed?
Adult fibroblasts are reprogrammed using a lentiviral stem cell cassette that introduces pluripotency factors.
What role does the adeno-Cre virus play?
The adeno-Cre virus is used to excise the stem cell cassette from the host genome, ensuring factor-free hiPSCs.
Can this methodology be applied to other cell types?
Yes, the methodology can be adapted for reprogramming various adult human cell types.
Executive Industry Relevance
This protocol addresses a critical bottleneck in regenerative medicine by delivering transgene-free human induced pluripotent stem cells (hiPSCs) under defined, xeno-free conditions suitable for clinical translation. By eliminating exogenous reprogramming factors and non-human antigens, the method enhances predictive confidence in target validation and reduces mechanistic ambiguity in preclinical models. The approach supports portfolio de-risking through reproducible generation of clinical-grade hiPSCs, enabling safer advancement of stem cell-derived therapeutics.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses using factor-free hiPSCs that eliminate confounding transgene expression.
- Operational Value: Provides a reproducible system for functional target validation without genomic integration artifacts.
- Predictive Value: Supports mechanistic de-risking by confirming pluripotency and absence of lentiviral remnants via quantitative PCR.
Screening & Assay Development
- Scientific Value: Generates standardized, feeder-free hiPSC lines suitable for assay development and compound screening.
- Operational Value: Ensures batch-to-batch consistency through defined xeno-free conversion and clonal selection.
- Scalability: Supports platform reuse across multiple cell types due to broad applicability of lentiviral reprogramming and excision.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery to preclinical validation by producing hiPSCs in GMP-compatible, xeno-free conditions.
- Biomarker Alignment: Enables monitoring of pluripotency markers (SOX2, OCT4, NANOG) and absence of non-human antigens via flow cytometry.
- Risk-Adjusted Advancement: Informs go/no-go decisions through confirmed excision of stem cell cassette and clinical-grade conversion.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early target validation through lead identification to preclinical efficacy testing, supporting scalable production of clinically relevant cell models.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification using transgene-free hiPSCs with validated pluripotency.
- Screening: Delivers assay-ready, clonal hiPSC lines with standardized morphology and marker expression for reproducible compound evaluation.
- Analytics: Enables quantitative assessment of reprogramming efficiency and genomic integrity via PCR-based excision confirmation and pluripotency marker quantification.
- Translational Research: Supports preclinical continuity by converting hiPSCs into defined, xeno-free conditions that mimic clinical manufacturing environments.
- Enterprise Reuse: Establishes a reusable platform for generating clinical-grade hiPSCs from diverse adult somatic cell sources.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence through factor-free, genetically stable hiPSCs with confirmed pluripotency and absence of viral remnants.
- Operational Value: Standardization and reproducibility via defined conversion workflows and quality-controlled clonal expansion.
- Strategic Value: Improved go/no-go decisions by reducing late-stage biological risk from transgene expression or xenogeneic contamination.
- Portfolio Impact: Enables risk-adjusted prioritization of stem cell-derived candidates based on validated clinical-grade conversion.
Implementation Considerations
- Requires expertise in stem cell culture, viral transduction, and molecular validation techniques.
- Dependent on lentiviral and adeno-Cre viral systems, necessitating BSL-2+ containment and appropriate safety protocols.
- Necessitates standardized qPCR and flow cytometry assays for excision confirmation and antigen screening.
- Requires adaptation to xeno-free substrates and defined media for clinical-grade conversion.
- Practical limitations include extended timeline for reprogramming, excision, and conversion phases, demanding sustained culture management.
Biopharma FAQs
Why is excision confirmation critical for target validation?
Excision confirmation ensures removal of the lentiviral stem cell cassette, eliminating risks of transgene expression that could confound target validation assays and compromise mechanistic interpretation in disease models.
How does genomic DNA analysis support preclinical model reliability?
Genomic DNA analysis using specific primers validates precise excision of the reprogramming factor, ensuring genetic integrity and reducing variability in preclinical readouts across experimental replicates.
What quantitative measurements enable assessment of reprogramming fidelity?
Quantitative PCR measurement of pluripotency-associated factors (SOX2, OCT4, NANOG) provides objective data on reprogramming efficiency and stability, enabling comparison between pre- and post-conversion hiPSC lines.
Why are replication requirements essential for cross-functional collaboration?
Replication requirements ensure consistent derivation of factor-free, clinical-grade hiPSCs across teams and sites, supporting reliable data sharing and comparative analysis in multidisciplinary drug discovery projects.
What statistical analysis capabilities are required before implementation?
Statistical analysis of qPCR and flow cytometry data is required to confirm significant differences in transgene excision and antigen expression, establishing thresholds for go/no-go decisions in therapeutic development.
Chapters in this video
0:05
Title
1:49
Reprogramming Adult Human Dermal Fibroblasts with STEMCCA
4:55
Vector Integration Site Analysis and STEMCCA Excision
7:08
Conversion into GMP-grade Conditions
8:50
Results: Reprogramming hiPSCs Using the STEMCCA Lentiviral Approach
9:59
Conclusion
